DrugPatentWatch Database Preview
Mechanism of Action: Cytochrome P450 3A Inhibitors
» See Plans and Pricing
Drugs with Mechanism of Action: Cytochrome P450 3A Inhibitors
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Amneal | ATAZANAVIR SULFATE | atazanavir sulfate | CAPSULE;ORAL | 209717-004 | Jun 1, 2020 | AB | RX | No | No | Start Trial | Start Trial | Start Trial | |||
Cipla | ATAZANAVIR SULFATE | atazanavir sulfate | CAPSULE;ORAL | 200626-001 | Aug 9, 2018 | AB | RX | No | No | Start Trial | Start Trial | Start Trial | |||
Cipla | ATAZANAVIR SULFATE | atazanavir sulfate | CAPSULE;ORAL | 200626-002 | Aug 9, 2018 | AB | RX | No | No | Start Trial | Start Trial | Start Trial | |||
Aurobindo Pharma Ltd | ATAZANAVIR SULFATE | atazanavir sulfate | CAPSULE;ORAL | 204806-001 | Jun 25, 2018 | AB | RX | No | No | Start Trial | Start Trial | Start Trial | |||
Cipla | ATAZANAVIR SULFATE | atazanavir sulfate | CAPSULE;ORAL | 200626-003 | Aug 9, 2018 | AB | RX | No | No | Start Trial | Start Trial | Start Trial | |||
Aurobindo Pharma Ltd | ATAZANAVIR SULFATE | atazanavir sulfate | CAPSULE;ORAL | 204806-002 | Jun 25, 2018 | AB | RX | No | No | Start Trial | Start Trial | Start Trial | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |